P116 Patient characteristics of biologic-experienced and biologic-naive patients with chronic plaque psoriasis receiving bimekizumab

Abstract The British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) is a prospective, observational cohort that records real-world psoriasis data in the UK and Ireland. Bimekizumab is a monoclonal immunoglobulin G1 antibody biologic that targets both interleukin-17A and interleukin-17F, and is approved for the treatment of both psoriasis and psoriatic arthritis in the UK. The aim of this study was to compare the patient characteristics of biologic-experienced and biologic-naive patients with chronic plaque psoriasis treated with bimekizumab. The BADBIR bimekizumab cohort included patients aged ≥ 18 years initiated on bimekizumab for chronic plaque psoriasis. The cohort was stratified into two subgroups: biologic-experienced and biologic-naive patients. Baseline patient characteristics were extracted, including biologic status, number of prior biologics, age of psoriasis onset, Psoriasis Area and Severity Index (PASI) and Dermatology Life Quality Index (DLQI) scores, psoriatic arthritis, comorbidities, site involvement, sex and disease duration. Overall, 326 patients were enrolled in the bimekizumab cohort (data lock: 1 August 2024). More patients were biologic experienced than biologic naive (Table). In the biologic-experienced subgroup, 70% (n = 182) of patients received two or more prior biologics. The average age of psoriasis onset, and PASI and DLQI scores were lower among patients with available data in the biologic-experienced subgroup than in the biologic-naive subgroup. Biologic-experienced patients had a higher rate of psoriatic arthritis and more comorbidities than those who were biologic naive. Both biologic-experienced and biologic-naive patients had high rates of high-impact site involvement, with scalp and nail psoriasis present. In conclusion, biologic-experienced patients receiving bimekizumab had a more complex patient profile, with multiple previous biologics and more comorbidities than those who were biologic naive. For those patients receiving bimekizumab who were biologic naive, most had greater disease severity and higher patient-reported quality-of-life scores than biologic-experienced patients. Further analysis might clarify whether these differences impact patient outcomes following bimekizumab treatment.TablePatient characteristics of biologic-experienced and biologic-naive patients with chronic plaque psoriasis treated with bimekizumab in BADBIRPatient characteristicsBiologic experiencedBiologic naiveP-valueNumber of patients, n (%)260 (79.8)66 (20.2)Age (years)44.0 (12.3)49.5 (14.4)< 0.001Male, n (%)156 (60.0)43 (65)0.44Disease duration (years)20.5 (12.6)21.5 (15.6)0.47Number of comorbidities2.0 (1.7)1.8 (1.7)< 0.001Age of psoriasis onset (years)23.5 (13.9)28.0 (16.1)0.10PASI score12.2 (9.1); n = 19616.9 (6.5); n = 630.001DLQI total score13.4 (8.0); n = 8219.8 (7.1); n = 360.005Psoriatic arthritis, n (%)89 (34.2)15 (23)0.07High-impact site involvement Scalp, n (%)189 (72.7)43 (65)0.23 Nail, n (%)130 (50.0)38 (58)0.27The results are the mean (SD), and from all patients in the subgroup unless indicated otherwise. DLQI, Dermatology Life Quality Index; PASI, Psoriasis Area and Severity Index.